Global Licensing Opportunities Hansa's deal transferring EU/MENA rights for Idefirix (imlifidase) outside the US to SERB demonstrates a proven licensing path and suggests ample opportunity to monetize remaining geographies such as the US, Asia, and LATAM. A targeted BD outreach to regional pharma partners could secure exclusive distribution or co-development deals to accelerate commercial launch and payer discussions in these markets.

Clinical Adoption Momentum US Phase 3 ConfIdeS data in kidney transplantation has been accepted as a late-breaking abstract at ATC, signaling strong clinical momentum and potential payer interest. Sales opportunities include engaging top transplant centers, key opinion leaders, and payer teams to plan adoption, evidence generation, and patient access programs.

Strategic BD Momentum With a new VP of Business Development and upcoming Capital Markets Day, Hansa appears to be accelerating its BD engine. This creates a path to structure high-potential partnerships, including co-development, milestone-driven deals, and regional distribution collaborations to expand global reach.

Commercial Capacity Ready The company reports revenue in a commercial-stage band and has a solid funding runway, providing bandwidth to support early adoption activities, medical education, and multi-channel access strategies in key transplant markets, while exploring selective distributor partnerships to scale sales coverage.

Ecosystem Partnership Potential Leadership visibility and industry engagement position Hansa to partner with hospital networks, reimbursement coalitions, and patient groups to accelerate access and expand indications beyond organ transplantation into IgG-mediated autoimmune conditions, gene therapy, and oncology where its immunomodulatory platform may add value.